Cart
Free Shipping in Australia
Proud to be B-Corp

Adenosine Receptors and Parkinson's Disease Hiroshi Kase (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan)

Adenosine Receptors and Parkinson's Disease By Hiroshi Kase (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan)

Adenosine Receptors and Parkinson's Disease by Hiroshi Kase (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan)


$18.99
Condition - Very Good
Only 1 left

Summary

Covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. This book provides an overview of adenosine antagonists and their role in the treatment of Parkinson's disease. It is intended for researchers interested in the basal ganglia, purine biology, and Parkinson's disease.

Adenosine Receptors and Parkinson's Disease Summary

Adenosine Receptors and Parkinson's Disease by Hiroshi Kase (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan)

This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.

About Hiroshi Kase (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan)

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson's disease. He has spent the major part of his career at King's College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King's College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson's disease patient-carer groups across the UK.

Table of Contents

H. Kase, Introductory Remarks: Adenosine A2A Receptor Antagonists: A Novel Approach to the Treatment of Parkinson's Disease. S.J. Augood, P.C. Emsom, and D.G. Standaert, Localisation of Adenosine Receptors in Brain and Periphery. J. Shimada and F. Suzuki, Medicinal Chemistry of Adenosine Receptors in Brain and Periphery. A. Karasawa, Overview of the Physiology and Pharmacology of Adenosine in the Peripheral System. H. Nonaka and M. Ichimura, Biochemical Characterizatoin of Adenosine Agonists and Antagonists. A. Mori and T. Shindou, Physiology of Adenosine Receptors in the Striatum: Regulation of Striatal Projection Neurons. P. Richardson and M. Kurokawa, The Regulation of Neurotransmitter Release in Basal Ganglia by Adenosine Receptor Agonists and Antagonists in Vitro and in Vivo. A. Dixon and P. Richardson, Control of Gene Expression in the Basal Ganglia Induced by Adenosine Receptors. S. Aoyama, J.-H. Baik, H. Kase, and E. Borrelli, Knockout Mice in the Study of Dopaminergic Diseases. S. Shiozaki, S. Ichikawa, J. Nakamura, and Y. Kuwana, Effects of Adenosine Receptors Experimental Models of Cognition and Motor Behaviour. T. Kanda and P. Jenner, Actions of Adenosine Antagonists in a Primate Model of Parkinson's Disease. A. Tahar, R. Grondin, L. Gregoire, A. Mori, H. Kase, and P.J. Bedard, Selective Adenosine A2A Receptor Antagonism as an Alternative Therapy for Parkinson's Disease: A Study in Nonhuman Primates. M. Nomoto, Neurobiology of Adenosine Receptors: Adenosine and its Metabolites in Movement Disorders.

Additional information

GOR007468729
9780124004054
0124004059
Adenosine Receptors and Parkinson's Disease by Hiroshi Kase (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan)
Used - Very Good
Hardback
Elsevier Science Publishing Co Inc
19991027
296
N/A
Book picture is for illustrative purposes only, actual binding, cover or edition may vary.
This is a used book - there is no escaping the fact it has been read by someone else and it will show signs of wear and previous use. Overall we expect it to be in very good condition, but if you are not entirely satisfied please get in touch with us

Customer Reviews - Adenosine Receptors and Parkinson's Disease